{"filing":{"accession_number":"0001193125-26-385194","cik":"0001652130","ticker":"NTLA","company_name":"Intellia Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"ntla-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526385194/ntla-20260908.htm"},"events":[{"id":31954,"run_id":29350,"accession_number":"0001193125-26-385194","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Intellia announced FDA acceptance of a Biologics License Application (BLA) with Priority Review for lonvo-z, a CRISPR-based therapy for hereditary angioedema, with a PDUFA target date of March 10, 2027. This represents a material regulatory milestone in the drug development and commercialization pathway for the company's lead product candidate.","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34997,"accession_number":"0001193125-26-385194","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Intellia announced FDA acceptance of a Biologics License Application (BLA) with Priority Review for lonvo-z, a CRISPR-based therapy for hereditary angioedema, with a PDUFA target date of March 10, 2027. This is a material regulatory milestone in the drug development and commercialization pathway—a key operational/strategic event for a biopharmaceutical company—but does not fit the specific categories of earnings_release, ma_activity, or other named types. The disclosure centers on regulatory progress toward potential product approval, making it an operational milestone rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:07:14.230052+00:00","company_name":"","ticker":null,"filing_date":""},{"id":34998,"accession_number":"0001193125-26-385194","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA acceptance of a Biologics License Application (BLA) for lonvo-z with Priority Review and a PDUFA target action date of March 10, 2027. This is a material regulatory milestone in the drug development and commercialization pathway for a lead product candidate. While this is a significant operational and strategic event for a biopharmaceutical company, it does not fit neatly into the specific event categories (e.g., it is not an earnings release, M\u0026A activity, or material litigation). The event is clearly operational/strategic in nature—a major regulatory approval milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:07:14.230052+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34997,"accession_number":"0001193125-26-385194","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Intellia announced FDA acceptance of a Biologics License Application (BLA) with Priority Review for lonvo-z, a CRISPR-based therapy for hereditary angioedema, with a PDUFA target date of March 10, 2027. This is a material regulatory milestone in the drug development and commercialization pathway—a key operational/strategic event for a biopharmaceutical company—but does not fit the specific categories of earnings_release, ma_activity, or other named types. The disclosure centers on regulatory progress toward potential product approval, making it an operational milestone rather than a financial or governance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:07:14.230052+00:00","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-09-08"},{"id":34998,"accession_number":"0001193125-26-385194","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces FDA acceptance of a Biologics License Application (BLA) for lonvo-z with Priority Review and a PDUFA target action date of March 10, 2027. This is a material regulatory milestone in the drug development and commercialization pathway for a lead product candidate. While this is a significant operational and strategic event for a biopharmaceutical company, it does not fit neatly into the specific event categories (e.g., it is not an earnings release, M\u0026A activity, or material litigation). The event is clearly operational/strategic in nature—a major regulatory approval milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:07:14.230052+00:00","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-09-08"}]}